enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [ 3 ] [ 14 ] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [ 15 ]

3. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Warfarin treatment requires blood monitoring and dose adjustments regularly due to its narrow therapeutic window. If supervision isn't adequate warfarin poses a threat in causing, all too frequent, haemorrhagic events and multiple interactions with food and other drugs.

4. Bristol-Myers Squibb and Pfizer Announce Publication of ...

   www.aol.com/news/2013-05-06-bristol-myers-squibb...

   Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation Subgroup analysis demonstrates that the treatment effects of Eliquis ® (apixaban) vs. warfarin, across ...

5. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Compared to warfarin it has fewer interactions with other medications. [12] It is a direct factor Xa inhibitor. [8] In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. [13] Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.

6. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

   www.aol.com/news/2012-10-01-eliquis-apixaban...

   The ARISTOTLE study was designed to demonstrate the efficacy and safety of ELIQUIS versus warfarin for the prevention of stroke or systemic embolism. In ARISTOTLE, 18,201 patients were randomized ...

7. Subanalysis of Phase III ARISTOTLE Trial of Eliquis ... - AOL

   www.aol.com/news/2013-09-03-subanalysis-of-phase...

   Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart ...

8. Direct thrombin inhibitor - Wikipedia

   en.wikipedia.org/wiki/Direct_thrombin_inhibitor

   Dabigatran is an oral direct thrombin inhibitor. Dabigatran (Pradaxa) was found to be noninferior to Warfarin in prevention of ischemic stroke, as well as intracranial hemorrhage risk and overall mortality for non-valvular atrial fibrillation according to the RE-LY trial. [9]

9. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

   www.aol.com/news/2013-01-02-us-fda-approves...

   U.S. FDA Approves ELIQUIS ® ... Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin in Three Key Outcomes—Stroke and Systemic ...